These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 23056330)

  • 1. Acute reactogenicity after intramuscular immunization with recombinant vesicular stomatitis virus is linked to production of IL-1β.
    Athearn K; Sample CJ; Barefoot BE; Williams KL; Ramsburg EA
    PLoS One; 2012; 7(10):e46516. PubMed ID: 23056330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant Isfahan Virus and Vesicular Stomatitis Virus Vaccine Vectors Provide Durable, Multivalent, Single-Dose Protection against Lethal Alphavirus Challenge.
    Nasar F; Matassov D; Seymour RL; Latham T; Gorchakov RV; Nowak RM; Leal G; Hamm S; Eldridge JH; Tesh RB; Clarke DK; Weaver SC
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28148802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heat shock protein 70 enhances mucosal immunity against human norovirus when coexpressed from a vesicular stomatitis virus vector.
    Ma Y; Duan Y; Wei Y; Liang X; Niewiesk S; Oglesbee M; Li J
    J Virol; 2014 May; 88(9):5122-37. PubMed ID: 24574391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus.
    Matassov D; Marzi A; Latham T; Xu R; Ota-Setlik A; Feldmann F; Geisbert JB; Mire CE; Hamm S; Nowak B; Egan MA; Geisbert TW; Eldridge JH; Feldmann H; Clarke DK
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S443-51. PubMed ID: 26109675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosal Delivery of Recombinant Vesicular Stomatitis Virus Vectors Expressing Envelope Proteins of Respiratory Syncytial Virus Induces Protective Immunity in Cotton Rats.
    Binjawadagi B; Ma Y; Binjawadagi R; Brakel K; Harder O; Peeples M; Li J; Niewiesk S
    J Virol; 2021 Feb; 95(6):. PubMed ID: 33408176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.
    Huttner A; Dayer JA; Yerly S; Combescure C; Auderset F; Desmeules J; Eickmann M; Finckh A; Goncalves AR; Hooper JW; Kaya G; Krähling V; Kwilas S; Lemaître B; Matthey A; Silvera P; Becker S; Fast PE; Moorthy V; Kieny MP; Kaiser L; Siegrist CA;
    Lancet Infect Dis; 2015 Oct; 15(10):1156-1166. PubMed ID: 26248510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in mice.
    Cooper D; Wright KJ; Calderon PC; Guo M; Nasar F; Johnson JE; Coleman JW; Lee M; Kotash C; Yurgelonis I; Natuk RJ; Hendry RM; Udem SA; Clarke DK
    J Virol; 2008 Jan; 82(1):207-19. PubMed ID: 17942549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment of replication-competent vesicular stomatitis virus recapitulating SADS-CoV entry.
    Zhu Z; Han Y; Gong M; Sun B; Zhang R; Ding Q
    J Virol; 2024 May; 98(5):e0195723. PubMed ID: 38557247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-Dose Trivalent VesiculoVax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge.
    Matassov D; Mire CE; Latham T; Geisbert JB; Xu R; Ota-Setlik A; Agans KN; Kobs DJ; Wendling MQS; Burnaugh A; Rudge TL; Sabourin CL; Egan MA; Clarke DK; Geisbert TW; Eldridge JH
    J Virol; 2018 Feb; 92(3):. PubMed ID: 29142131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates.
    Mire CE; Miller AD; Carville A; Westmoreland SV; Geisbert JB; Mansfield KG; Feldmann H; Hensley LE; Geisbert TW
    PLoS Negl Trop Dis; 2012; 6(3):e1567. PubMed ID: 22448291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Recombinant VSV-Based Bivalent Vaccine Effectively Protects against Both SARS-CoV-2 and Influenza A Virus Infection.
    Ao Z; Ouyang MJ; Olukitibi TA; Warner B; Vendramelli R; Truong T; Meilleur C; Zhang M; Kung S; Fowke KR; Kobasa D; Yao X
    J Virol; 2022 Sep; 96(18):e0133722. PubMed ID: 36069551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal immunization with recombinant vesicular stomatitis virus expressing murine cytomegalovirus glycoprotein B induces humoral and cellular immunity.
    Wilson SR; Wilson JH; Buonocore L; Palin A; Rose JK; Reuter JD
    Comp Med; 2008 Apr; 58(2):129-39. PubMed ID: 18524170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rhabdovirus-based vaccine platforms against henipaviruses.
    Kurup D; Wirblich C; Feldmann H; Marzi A; Schnell MJ
    J Virol; 2015 Jan; 89(1):144-54. PubMed ID: 25320306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment.
    Clarke DK; Hendry RM; Singh V; Rose JK; Seligman SJ; Klug B; Kochhar S; Mac LM; Carbery B; Chen RT;
    Vaccine; 2016 Dec; 34(51):6597-6609. PubMed ID: 27395563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vesicular stomatitis virus as a vector to deliver virus-like particles of human norovirus: a new vaccine candidate against an important noncultivable virus.
    Ma Y; Li J
    J Virol; 2011 Mar; 85(6):2942-52. PubMed ID: 21228240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern.
    Lu M; Chamblee M; Zhang Y; Ye C; Dravid P; Park JG; Mahesh KC; Trivedi S; Murthy S; Sharma H; Cassady C; Chaiwatpongsakorn S; Liang X; Yount JS; Boyaka PN; Peeples ME; Martinez-Sobrido L; Kapoor A; Li J
    Proc Natl Acad Sci U S A; 2022 Aug; 119(35):e2110105119. PubMed ID: 35994646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the immunogenicity of nasal-spray rVSV vector, adenovirus vector, and inactivated COVID-19-based vaccines in rodent models.
    Zhang Y; Liu J; Li H; Yuan F; Jiang C; Cang T; Li K; Hu Q; Liu J; Zheng A
    J Med Virol; 2023 May; 95(5):e28806. PubMed ID: 37219050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-Vector, Single-Injection Recombinant Vesicular Stomatitis Virus Vaccines Against High-Containment Viruses.
    Whitt MA; Geisbert TW; Mire CE
    Methods Mol Biol; 2016; 1403():295-311. PubMed ID: 27076138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma.
    Shin EJ; Wanna GB; Choi B; Aguila D; Ebert O; Genden EM; Woo SL
    Laryngoscope; 2007 Feb; 117(2):210-4. PubMed ID: 17204993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Immunogenicity of a Recombinant Vesicular Stomatitis Virus-Vectored Marburg Vaccine in Cynomolgus Macaques.
    Camargos VN; Rossi SL; Juelich TL; Smith JK; Vasilakis N; Freiberg AN; Nichols R; Fusco J
    Viruses; 2024 Jul; 16(8):. PubMed ID: 39205155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.